| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 630 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | PTGX Protagonist Therapeutics, Inc. | Patel Dinesh V Ph D | President And CEO | Sell | 75,000 | $100.12 | $7,509,000.00 | -12.5% | - | - | |
| May 12, 2026 | HOWL Werewolf Therapeutics, Inc. | Evnin Luke55 | Director | Sell | 407,574 | $0.69 | $280,210.26 | -10.0% | - | - | |
| May 11, 2026 | MPLT Maplight Therapeutics, Inc. | Hanson Kristopher | General Counsel | Sell | 13,917 | $30.13 | $419,263.08 | -2.0% | - | - | |
| May 11, 2026 | ODTX Odyssey Therapeutics, Inc. | Sr One Capital Management, LLC52 | 10% Owner | Sell | 1,780 | $18.00 | $32,040.00 | - | - | - | |
| May 11, 2026 | ARQT Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | Sell | 222 | $21.05 | $4,673.10 | -0.2% | - | - | |
| May 11, 2026 | ARQT Arcutis Biotherapeutics, Inc. | Vairavan Latha | SVP Chief Financial Officer | Sell | 435 | $21.05 | $9,156.75 | -0.5% | - | - | |
| May 11, 2026 | ODTX Odyssey Therapeutics, Inc. | Sr One Capital Management, LLC52 | 10% Owner | Buy | 555,555 | $18.00 | $9,999,990.00 | +19.4% | - | - | |
| May 11, 2026 | ZVRA Zevra Therapeutics, Inc. | Thompson Rahsaan | Chief Legal &Compliance | Sell | 1,794 | $11.30 | $20,272.20 | -3.6% | - | - | |
| May 11, 2026 | ARTV Artiva Biotherapeutics, Inc. | Ra Capital Management, L.P.53 | Director, 10% Owner | Buy | 6,510,416 | $11.52 | $74,999,992.32 | +74.9% | - | - | |
| May 11, 2026 | JANX Janux Therapeutics, Inc. | Dobek Maria | Vice President, Accounting | Sell | 2,038 | $14.17 | $28,878.46 | -5.9% | - | - | |
| May 11, 2026 | SION Sionna Therapeutics, Inc. | Thompson Peter A.65 | Director | Sell | 292,952 | $45.62 | $13,364,064.50 | -3.4% | - | - | |
| May 11, 2026 | MPLT Maplight Therapeutics, Inc. | Kroeger Christopher A. | Chief Executive Officer | Sell | 68,491 | $28.47 | $1,949,634.12 | -0.5% | - | - | |
| May 11, 2026 | COAG Hemab Therapeutics Holdings, Inc. Common Stock | Ra Capital Management, L.P.53 | 10% Owner | Buy | 51,258 | $24.75 | $1,268,594.26 | +0.2% | - | - | |
| May 8, 2026 | ODTX Odyssey Therapeutics, Inc. | Dimension Capital Ii, L.P. | Director | Buy | 1,111,111 | $18.00 | $19,999,998.00 | +50.0% | - | - | |
| May 7, 2026 | VCEL Vericel Corporation | Mara Joseph Anthony Jr | Chief Financial Officer | Sell | 5,000 | $40.50 | $202,500.00 | -19.2% | - | - | |
| May 7, 2026 | MPLT Maplight Therapeutics, Inc. | Foff Erin Pennock | Chief Medical Officer | Sell | 4,438 | $28.54 | $126,639.62 | -0.6% | - | - | |
| May 7, 2026 | EXEL Exelixis, Inc. | Beckerle Mary C50 | Director | Sell | 7,712 | $48.45 | $373,646.40 | -30.6% | - | - | |
| May 7, 2026 | MPLT Maplight Therapeutics, Inc. | Lillie James Woodruff | Chief Scientific Officer | Sell | 721 | $28.28 | $20,389.88 | -0.3% | - | - | |
| May 7, 2026 | VCEL Vericel Corporation | Siegal Jonathan64 | Principal Accounting Officer | Sell | 4,855 | $38.73 | $188,045.00 | -57.0% | - | - | |
| May 6, 2026 | BLTE Belite Bio, Inc | Mata Nathan L. | Chief Scientific Officer | Sell | 1,000 | $153.84 | $153,838.71 | -13.7% | - | - | |
| May 6, 2026 | MBX Mbx Biosciences, Inc. | Azoulay Salomon | Chief Medical Officer | Sell | 231 | $29.54 | $6,823.74 | -1.5% | - | - | |
| May 6, 2026 | MBX Mbx Biosciences, Inc. | Hawryluk P. Kent83 | President &CEO | Sell | 607 | $29.54 | $17,930.78 | - | - | - | |
| May 6, 2026 | AVTX Avalo Therapeutics, Inc. | Chan Mitchell | Director | Sell | 3,167 | $22.88 | $72,460.96 | -50.0% | - | - | |
| May 6, 2026 | NGNE Neurogene Inc. | Cvijic Christine Mikail | President And CFO | Sell | 9,600 | $31.25 | $300,043.20 | -4.8% | - | - | |
| May 6, 2026 | GYRE Gyre Therapeutics, Inc. | Luo Ying | Chief Executive Officer | Sell | 10,315 | $8.04 | $82,927.23 | -0.2% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.